IMA is loading

Main Financial Data 2009

Main Data: 31/12 Year 2009
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 505.77
– gross industrial income 217.47
– total operating cost 146.33
– operating profit 71.14
– net financial expenses 10.09
– group profit 36.86

 

Consolidated balance sheet Millions/Euro
– working capital 98.93
– non-current assets 161.41
– provision for severance indemnities and other provisions – 16.71
– net debt – 113.43
– equity pertaining to the group and minority interests 130.20

 

Other information Millions/Euro
– depreciation, amortization and impairment 15.21
– R & D costs 25.95

 

  Euro
Dividend per share 0.90

 

  No.
Employees 3,135

 

  Euro
Share capital 17,732,000

 

Main Data: 30/06 Year 2009
Consolidated income statement (international practice in accordance with IAS/IFRS) Millions/Euro
– total revenues 237.4
– gross industrial income 103.3
– total operating cost 73.7
– operating profit 29.6
– net financial expenses 6.9
– gruop profit 13.9

 

Consolidated balance sheet Millions/Euro
– working capital 113.6
– non-current assets 187.1
– provision for severance indemnities and other provisions – 24.0
– net debt – 168.7
– equity pertaining to the group and minority interests 108.0

 

Other information Millions/Euro
– depreciation, amortization and impairment 7.2
– R & D costs 14.7

 

  No.
Employees 3,126

 

  Euro
Share capital 17,732,000

 

Net Sales by Sector: Year 2009
  Millions/Euro  
tea, herbs & coffee 93.79 18.5%
pharmaceuticals packaging 292.91 58.0%
pharmaceuticals processing 119.07 23.5%
Total 505.77 100.0%

 

Net Sales by Country: Year 2009
  Millions/Euro  
E.U. (excluding Italy) 193.79 38.3%
Other European countries 36.28 7.2%
North America 76.40 15.1%
Asia & Middle East 118.24 23.4%
Other countries 44.12 8.7%
Total exports 468.83 92.7%
Italy 36.94 7.3%
Total 505.77 100.0%